Chemerin and Asprosin as Promising Biomarkers of Metabolic Syndrome: A Scoping Review

In this review, current evidence on the levels of chemerin and asprosin, which are promising adipokines in metabolic syndrome, their mechanisms of action, and their relationship with inflammation, diet and lifestyle in metabolic syndrome, and their effects on metabolic syndrome are reviewed.

Metabolic syndrome is a pro-inflammatory condition characterized by the coexistence of risk factors such as atherogenic dyslipidemia, high blood pressure, abdominal obesity, insulin resistance and higher blood glucose levels, cardiovascular diseases and type 2 diabetes etc. related with increased risk of developing chronic diseases. In recent years, chemerin and asprosin, the new players of metabolic syndrome, whose incidence has been increasing with the changing world, have attracted attention as predictive biomarkers in metabolic syndrome. These two adipokines seem to mediate the systemic pro-inflammatory state of individuals with metabolic syndrome. There is information that chemerin and asprosin levels are mostly increased in individuals with metabolic syndrome and that their levels can be altered or unaffected by dietary and lifestyle factors. However, conflicting results in the literature indicate that more studies are needed.

With the adoption of healthy lifestyle habits through healthy diet and exercise interventions, chemerin and asprosin hold promise for early detection, prevention and treatment strategies of metabolic syndrome.

Full size image